OverviewSuggest Edit

Gritstone Oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. Its initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer.

TypePublic
Founded2015
HQEmeryville, CA, US
Websitegritstoneoncology.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Feb 2019)102(+2%)
Job Openings32
Revenue (FY, 2020)$4 M(-7%)
Share Price (Sept 2021)$11.3(-3%)
Cybersecurity ratingAMore

Key People/Management at Gritstone Oncology

Andrew Allen

Andrew Allen

Co-Founder, President and Chief Executive Officer, Director
Celia Economides

Celia Economides

Executive Vice President and Chief Financial Officer
Erin E. Jones

Erin E. Jones

Chief Operating Officer
Matthew Hawryluk

Matthew Hawryluk

Executive Vice President and Chief Business Officer
Stacy Proctor

Stacy Proctor

Senior Vice President and Head of People
Raphaël F. Rousseau

Raphaël F. Rousseau

Executive Vice President and Chief Medical Officer
Show more

Gritstone Oncology Office Locations

Gritstone Oncology has offices in Emeryville, Cambridge and Pleasanton
Emeryville, CA, US (HQ)
5959 Horton St #300
Cambridge, MA, US
40 Erie St #120
Pleasanton, CA, US
4698 Willow Rd
Show all (3)

Gritstone Oncology Financials and Metrics

Gritstone Oncology Revenue

Gritstone Oncology's revenue was reported to be $4.04 m in FY, 2020
USD

Revenue (Q1, 2021)

39.7m

Net income (Q1, 2021)

7.9m

EBIT (Q1, 2021)

7.9m

Market capitalization (22-Sept-2021)

557.9m

Closing stock price (22-Sept-2021)

11.3

Cash (31-Mar-2021)

108.5m

EV

473.1m
Gritstone Oncology's current market capitalization is $557.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.2m4.4m4.0m

General and administrative expense

5.1m6.1m11.8m19.4m21.4m

R&D expense

13.9m35.7m55.0m82.9m88.6m

Operating expense total

19.0m41.8m66.8m102.3m110.1m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

96.0k1.3m1.2m984.0k1.3m488.0k939.0k39.7m

General and administrative expense

3.1m4.4m4.8m4.6m5.5m5.3m5.0m6.9m

R&D expense

15.6m15.9m18.5m24.9m22.5m21.3m22.1m24.9m

Operating expense total

18.7m20.3m23.4m29.5m27.9m26.5m27.1m31.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

12.4m39.0m52.2m57.4m170.1m

Prepaid Expenses

884.0k2.5m4.5m3.5m4.3m

Current Assets

38.4m88.5m157.6m131.3m175.4m

PP&E

7.5m27.2m29.5m26.9m22.1m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

37.5m65.9m34.6m107.7m116.9m54.9m62.6m57.6m108.5m

Prepaid Expenses

2.4m6.7m2.8m3.5m5.3m3.5m2.6m3.2m4.5m

Current Assets

66.9m84.2m135.0m184.7m154.8m112.3m94.5m73.7m202.5m

PP&E

27.5m27.0m15.7m19.0m24.4m25.8m24.6m23.3m21.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.7m)(41.4m)(64.8m)(94.4m)(105.3m)

Depreciation and Amortization

823.0k2.0m4.0m4.7m6.6m

Accounts Payable

(760.0k)2.3m3.2m45.0k826.0k

Cash From Operating Activities

(15.3m)(35.0m)(38.2m)(85.0m)(89.1m)
Quarterly
USDQ2, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(14.6m)(28.8m)(47.4m)(18.0m)(39.2m)(66.7m)(26.2m)(52.1m)7.9m

Depreciation and Amortization

846.0k1.9m2.9m1.0m2.1m3.3m1.6m5.0m1.6m

Accounts Payable

122.0k(177.0k)179.0k(235.0k)(867.0k)1.6m865.0k599.0k(200.0k)1.6m

Cash From Operating Activities

(13.0m)(27.1m)(25.2m)(19.1m)(37.5m)(62.6m)(23.0m)(43.7m)(63.9m)10.7m
USDFY, 2016

Financial Leverage

1.1 x
Show all financial metrics

Gritstone Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Gritstone Oncology Online and Social Media Presence

Embed Graph

Gritstone Oncology News and Updates

Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced it is changing its name to Gritstone bio, Inc. effective immediately…

Gritstone Oncology shares soar 44% premarket on news of collaboration with Gilead to develop HIV therapy

Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to use Gritstone's vaccine platform technology to develop a treatment for HIV. "Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Grit…

Gritstone Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and c…

Gritstone Oncology Announces Private Placement Financings Totaling $125 Million

--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing----Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next genera…

Gritstone Oncology Announces $110 Million Private Placement

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to rai…

Gritstone Oncology Announces Updated Presentation Time at Cantor Virtual Global Healthcare Conference

EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and …
Show more

Gritstone Oncology Frequently Asked Questions

  • When was Gritstone Oncology founded?

    Gritstone Oncology was founded in 2015.

  • Who are Gritstone Oncology key executives?

    Gritstone Oncology's key executives are Andrew Allen, Celia Economides and Erin E. Jones.

  • How many employees does Gritstone Oncology have?

    Gritstone Oncology has 102 employees.

  • What is Gritstone Oncology revenue?

    Latest Gritstone Oncology annual revenue is $4 m.

  • What is Gritstone Oncology revenue per employee?

    Latest Gritstone Oncology revenue per employee is $39.6 k.

  • Who are Gritstone Oncology competitors?

    Competitors of Gritstone Oncology include Burning Rock Biotech, Virta Health and RichFeel.

  • Where is Gritstone Oncology headquarters?

    Gritstone Oncology headquarters is located at 5959 Horton St #300, Emeryville.

  • Where are Gritstone Oncology offices?

    Gritstone Oncology has offices in Emeryville, Cambridge and Pleasanton.

  • How many offices does Gritstone Oncology have?

    Gritstone Oncology has 3 offices.